Diabetic patients with ovarian cancer who took the drug metformin because of their diabetes had a better survival rate than patients who did not get it, a survey headed by Mayo Clinic shows. The findings, published early online within the journal Cancer, may play a crucial role for researchers because they study the employment of existing medications to treat different or new diseases.
Researchers compared the survival of 61 patients with ovarian cancer taking metformin and 178 patients have been not taking metformin. Sixty-seven percent of the patients who took metformin were surviving after five years, weighed against 47 percent of those who would not make medication. If your researchers analyzed factors such as patients’ bmi, the degree of the cancer, type of chemotherapy and excellence of surgery, they found that patients taking metformin were nearly four times likelier to outlive, in comparison with those not implementing these the medication.
“Our study demonstrated improved survival in women with ovarian cancer which were taking metformin,” says co-author Sanjeev Kumar, M.B.B.S., a Mayo Clinic gynecologic oncology fellow. “The effects are encouraging, but services or products retrospective study, many factors are not controlled for many people to express when there is an immediate expected outcomes. Rather, this can be further human evidence for a potential beneficial effect of an commonly used drug which can be relatively safe in humans. These findings must provide impetus for prospective clinical trials in ovarian cancer.”
The outcomes may pave just how for utilizing metformin in large-scale randomized trials in ovarian cancer, researchers say. Given the high death rate of ovarian cancer, researchers say there exists a great have to develop new therapies for ovarian cancer. Metformin may potentially be one of those options.
Source: Mayo Clinic
Copyright 2012 Medimoon.com. All rights reserved. No part of this site can be reproduced without our written permission.